Today: 18 January 2026
Subscribe
Browse Category

Mergers & Acquisitions News 10 October 2025 - 15 October 2025

Shocking Surge: Hillenbrand Stock Soars 19% on $32 Buyout Announcement

Shocking Surge: Hillenbrand Stock Soars 19% on $32 Buyout Announcement

Lone Star Buyout Details Hillenbrand (NYSE: HI) announced on Oct. 15 that it will be acquired by Lone Star Funds in an all-cash deal at $32.00 per share Hillenbrand. At this price, the transaction’s enterprise value is roughly $3.8 billion, including Hillenbrand’s debt. The board said it reviewed multiple strategic options and unanimously determined the offer “is in the best interest of…
15 October 2025
····
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases Omeros. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rights Omeros Reuters. Reuters reports that Omeros…
15 October 2025
····
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties…
15 October 2025
···
Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

HOND stock has surged into the mid-$20s (around $24.98 as of Oct. 15, 2025) after trading in the high teens last week Investing Marketbeat. Its volume spiked (about 1.14 million shares on Oct. 13) and the stock gapped up from $18.86 to $21.69 at open on Oct. 13 Marketbeat. – The catalyst is a proposed merger with Terrestrial Energy Inc.,…
15 October 2025
···
Urban-gro Stock Skyrockets on Flashy Merger Deal – Is This the Cannabis Builder’s Comeback?

Urban-gro Stock Skyrockets on Flashy Merger Deal – Is This the Cannabis Builder’s Comeback?

Merger with Flash Sports & Media Sparks Stock Surge Urban-gro’s announcement of a planned merger with Flash Sports & Media sent its battered stock soaring on October 14. The company revealed it signed a binding LOI to combine with Flash, a private sports-media firm, in what is effectively a reverse merger Tipranks. Under the proposal, Flash will be absorbed into…
14 October 2025
····
Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Latest News & Developments On Oct. 14, 2025, Astria was swept into the headlines by a surprise $700+ million takeover. BioCryst Pharmaceuticals announced a definitive merger agreement to acquire Astria for $8.55 in cash plus 0.59 shares of BioCryst stock per Astria share (≈$13.00 total) Marketscreener Reuters. This values Astria at roughly $920M equity and $700M enterprise Stocktitan. The Boards…
14 October 2025
····
BlackRock’s GIP Poised for $38B AES Power Grab – AI-Fuelled Demand Sparks Takeover Frenzy

BlackRock Soars: Crypto ETFs, AI Funds and Mega M&A Propel Assets to Record $13.5T

BlackRock’s latest earnings and moves underscore its market heft and broad strategy. CEO Larry Fink observed that “record demand” across the firm’s businesses — from technology-driven funds to private credit and ETFs — powered the quarter Reuters. In particular, strong flows into lower-cost index and cash products (helped by the Fed’s recent rate cut) drove the fee bump. An analyst…
14 October 2025
···
EasyJet Stock Skyrockets on Takeover Rumours – MSC Denies Interest

EasyJet Stock Skyrockets on Takeover Rumours – MSC Denies Interest

What’s Happening? On Oct 14 an Italian newspaper (Corriere della Sera) reported that MSC, the world’s largest container-ship operator, is exploring a bid for EasyJet. The report said MSC might team up with an investment fund to buy a stake or even full control of the UK airline Proactiveinvestors Marketscreener. In early London trading EasyJet stock soared (hitting 11.5% gains)…
14 October 2025
····
PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

Company Overview PMGC Holdings Inc. (NASDAQ: ELAB) is a diversified holding company that grows by acquisitions. Its profile describes it as managing a portfolio of subsidiaries through strategic deals Reuters. Notably, one subsidiary – NorthStrive Biosciences – is a biopharma/medtech firm developing aesthetic and obesity-related treatments (e.g. an engineered probiotic “EL-22” for muscle retention) Reuters. The other arms (PMGC Research,…
14 October 2025
····
Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Overview of Strive and Its Role: Strive Asset Management began as an ETF issuer and anti-ESG investment firm (co-founded by Ramaswamy in 2022) Etf Globenewswire. In 2025 it transformed into a dedicated Bitcoin-treasury company. Strive’s business is to raise capital (through equity/debt) and convert it into Bitcoin holdings. The company uses a “preferred equity only” leverage model (no debt) to…
11 October 2025
····
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases Protagonist Inc. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers…
11 October 2025
····
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonist Reuters. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that J&J is negotiating a purchase of Protagonist Therapeutics Reuters. This potential acquisition would build on the companies’ ongoing partnership: J&J’s…
10 October 2025
····
1 … 29 30 31 32 33 34

Stock Market Today

  • Nvidia stock muted after China blocks H200 shipments; traders eye earnings and AI-chip roadmap
    January 18, 2026, 1:53 PM EST. NVIDIA shares closed down 0.41% to $186.23 on Friday after a Financial Times report that Chinese customs blocked shipments of the H200 AI processor. Suppliers paused output as the halt looms over Nvidia's supply chain. With markets closed for MLK Day, focus shifts to Tuesday's session and Nvidia's Feb. 25 results. Analysts at Wolfe Research keep Nvidia on the Alpha List, citing a ramp for Blackwell and Rubin chips; they see upside to 2026 revenue if the trend holds. Options activity could amplify moves ahead of expiration. A pause that drags into a formal ban would delay shipments; a temporary pause could ease near-term pressure. The broader semis index rose, but the China hinge remains.
Go toTop